+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in the treatment of gastrointestinal stromal tumors



Recent advances in the treatment of gastrointestinal stromal tumors



Therapeutic Advances in Medical Oncology 6(3): 115-127



Constitutively activating mutations in the KIT and platelet-derived growth factor receptor α (PDGFRA) RTKs play a crucial role in the biology of gastrointestinal stromal tumors (GISTs), and this disease has served as an effective model for targeting gain-of-function kinase mutations in cancer. Imatinib has entered the clinical arena in the last decade and substantially improved the outcome in these formerly untreatable cancers. However, most advanced GISTs responding to imatinib progress within 2-3 years due to heterogeneous subclones harboring a range of imatinib-resistant secondary KIT mutations. Sunitinib, and more recently, regorafenib, have obtained US Food and Drug Administration approval for the treatment of GISTs after imatinib failure, and thus expanded the treatment options in resistant disease. Within this framework, we present an evaluation of current GIST management, emphasizing the most recent advances in the field together with a discussion on future steps to be taken in refractory disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 055399337

Download citation: RISBibTeXText

PMID: 24790651

DOI: 10.1177/1758834014522491


Related references

Recent advances in the management of gastrointestinal stromal tumors. F1000 Medicine Reports 2: -, 2010

Recent advances in the management of gastrointestinal stromal tumors. Current Oncology Reports 5(4): 288-294, 2003

Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports 9(3): 165-169, 2007

Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology 30(10): 1213-1220, 1999

Pharmacological treatment of gastrointestinal stromal tumors: update from recent clinical trials. Clinical Investigation 2(5): 537-544, 2012

Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. Expert Review of Anticancer Therapy 1(2): 258-268, 2002

Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Current Opinion in Oncology 17(4): 386-391, 2005

Dedifferentiated gastrointestinal stromal tumor: Recent advances. Annals of Diagnostic Pathology 2019, 2019

Recent advances in managing gastrointestinal stromal tumor. F1000research 6: 1689-1689, 2017

Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 11(1): 27-33, 2007

Recent advances and novel agents for gastrointestinal stromal tumor GIST. Journal of Hematology & Oncology 5(1): 21, 2012

Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Journal of Hematology & Oncology 5: 21-21, 2012

Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathology International 65(1): 9-18, 2015

Advances and Challenges on Management of Gastrointestinal Stromal Tumors. Frontiers in Oncology 8: 135-135, 2018

Latest advances in adult gastrointestinal stromal tumors. Future Oncology 13(24): 2183-2193, 2017